Delivering high quality affordable medicines to millions of patients worldwide
Glenmark has worked towards improving the lives of patients globally. In the pursuit of this mission, Glenmark has focused on the development of products that cater to the unmet medical needs. Glenmark's has primarily been structured into Drug Discovery and Development, Branded and Generic Formulations and Active Pharmaceutical Ingredients.
Research & Development
Innovation is at the core of everything we do. It has been our endeavor to continuously innovate to improve lives of patients globally. In this quest, Glenmark is committed to address needs in the therapy areas of dermatology, oncology, respiratory, pain and autoimmune disorders. Today, we have a strong pipeline of novel molecules, both New Chemical Entities (NCEs) and New Biological Entities (NBEs), in pre-clinics or in various stages clinical development.
Focus on high quality formulations
Glenmark has focused on developing branded and generic formulations for over 3 decades positively impacting lives globally. In branded formulations, we are focused on developing innovative products for markets such as India, Russia & CIS, Brazil, Asia and Africa. The focus has been to develop products across dermatology, respiratory, cardio-metabolic therapy areas for the patients. In generics, we are developing high quality affordable products for markets such as US and Europe.
Active Pharmaceutical Ingredients
Glenmark's API division manufactures and supplies more than 190 high quality APIs to customers worldwide. Glenmark partners with leading global generic companies, by supporting partnerships through advanced process chemistry skills and innovative intellectual property. Our API business spans over 80 countries including regulated markets of the US, Canada, Europe and Japan. Glenmark is a market leader for many API products in semi-regulated markets and has also established a leadership position with its first-to-file offerings in regulated markets.